Opinion|Videos|November 27, 2024
Real-World Outcomes in HER2-Positive NSCLC
Dr Heymach real-world outcomes versus clinical trials for HER2-positive NSCLC and the management of common adverse events associated with HER2-directed therapies.
Advertisement
Video content above is prompted by the following:
- How do real-world patient outcomes for patients with HER 2 positive NSCLC compare to those seen in clinical trials?
- What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- BCMA-Targeted Bispecific Antibodies: Navigating the New Frontier of Myeloma
September 17th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
2
Metabolic Issues More Common in Patients With HIV
3
Iron Dysregulation Linked to MS Progression, Review Finds
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5